[go: up one dir, main page]

WO2007074456A3 - Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids - Google Patents

Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids Download PDF

Info

Publication number
WO2007074456A3
WO2007074456A3 PCT/IL2006/001494 IL2006001494W WO2007074456A3 WO 2007074456 A3 WO2007074456 A3 WO 2007074456A3 IL 2006001494 W IL2006001494 W IL 2006001494W WO 2007074456 A3 WO2007074456 A3 WO 2007074456A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenylalanine
cysteine
cxcr4
aminoacids
cell motility
Prior art date
Application number
PCT/IL2006/001494
Other languages
French (fr)
Other versions
WO2007074456A2 (en
Inventor
Tsvee Lapidot
Menachem Rubinstein
Asaf Spiegel
Mati Fridkin
Alexander Kalinkovich
Shoham Shivtiel
Original Assignee
Yeda Res & Dev
Tsvee Lapidot
Menachem Rubinstein
Asaf Spiegel
Mati Fridkin
Alexander Kalinkovich
Shoham Shivtiel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Tsvee Lapidot, Menachem Rubinstein, Asaf Spiegel, Mati Fridkin, Alexander Kalinkovich, Shoham Shivtiel filed Critical Yeda Res & Dev
Priority to CA002635770A priority Critical patent/CA2635770A1/en
Priority to AU2006329534A priority patent/AU2006329534A1/en
Priority to JP2008548073A priority patent/JP2009521917A/en
Priority to EP06821674A priority patent/EP1971356A2/en
Publication of WO2007074456A2 publication Critical patent/WO2007074456A2/en
Publication of WO2007074456A3 publication Critical patent/WO2007074456A3/en
Priority to IL192372A priority patent/IL192372A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to phenylalanine, cysteine, derivatives of said amino acids, peptides comprising them, and to their use in diseases disorders or conditions whose pathology is caused by or associated with CXCR4 activity and/or cell motility.
PCT/IL2006/001494 2005-12-29 2006-12-27 Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids WO2007074456A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002635770A CA2635770A1 (en) 2005-12-29 2006-12-27 Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids
AU2006329534A AU2006329534A1 (en) 2005-12-29 2006-12-27 Inhibition of CXCR4 and/or cell motility by phenylalanine, cysteine or peptides containing said amino acids
JP2008548073A JP2009521917A (en) 2005-12-29 2006-12-27 Inhibition of CXCR4 and / or cell motility
EP06821674A EP1971356A2 (en) 2005-12-29 2006-12-27 Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids
IL192372A IL192372A0 (en) 2005-12-29 2008-06-22 Inhibition of cxcr4 and/or cell motility

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL172896A IL172896A0 (en) 2005-12-29 2005-12-29 Cxcr4 inhibition
IL172896 2005-12-29

Publications (2)

Publication Number Publication Date
WO2007074456A2 WO2007074456A2 (en) 2007-07-05
WO2007074456A3 true WO2007074456A3 (en) 2008-05-29

Family

ID=38093072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/001494 WO2007074456A2 (en) 2005-12-29 2006-12-27 Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids

Country Status (6)

Country Link
EP (1) EP1971356A2 (en)
JP (1) JP2009521917A (en)
AU (1) AU2006329534A1 (en)
CA (1) CA2635770A1 (en)
IL (2) IL172896A0 (en)
WO (1) WO2007074456A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066858A1 (en) * 2008-12-10 2010-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the prognosis of cancer
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
US8815806B2 (en) 2009-10-28 2014-08-26 University Of Manitoba Yellow pea seed protein-derived peptides
KR102205512B1 (en) 2012-11-13 2021-01-20 아도시아 Quick-acting insulin formulation including a substituted anionic compound
FR3020947B1 (en) 2014-05-14 2018-08-31 Adocia AQUEOUS COMPOSITION COMPRISING AT LEAST ONE PROTEIN AND A SOLUBILIZING AGENT, ITS PREPARATION AND ITS USES
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3043557B1 (en) 2015-11-16 2019-05-31 Adocia RAPID ACID COMPOSITION OF INSULIN COMPRISING A SUBSTITUTED CITRATE
WO2019185907A1 (en) * 2018-03-29 2019-10-03 Universite Paris Est Creteil Val De Marne Phenylalanine derivatives for use in the treatment of cancers
DE102020201019A1 (en) * 2020-01-29 2021-07-29 Beiersdorf Aktiengesellschaft Allergen protection for the skin
CN111574597B (en) * 2020-05-07 2023-03-31 中国科学院微生物研究所 anti-HIV polypeptide modified by high molecular weight PEG (polyethylene glycol), preparation method and application thereof

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01146817A (en) * 1987-12-02 1989-06-08 Norio Shimura Agent for alleviating acquired immune deficiency syndrome
EP0443891A1 (en) * 1990-01-25 1991-08-28 Adir Et Compagnie Use of N-myristoyl-(S)-phenylalanine for the preparation of a medicament for the treatment of disorders by inhibiting the myristoylation
WO1992021368A1 (en) * 1991-06-06 1992-12-10 Life Sciences' Technologies, Inc. Composition and method for disease treatment
DE19734161A1 (en) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh Antagonists of stroma cell-derived factor-1, for diagnosis and treatment of human immune deficiency virus (HIV) infection
WO1999056764A1 (en) * 1998-04-30 1999-11-11 Teijin Limited Method for preventing or treating a human immunodeficiency virus infection
WO1999065479A1 (en) * 1998-06-19 1999-12-23 Bryan Thomas B Method of treating an autoimmune disorder
EP1004302A2 (en) * 1998-10-29 2000-05-31 Ajinomoto Co., Ltd. Immunomodulator
WO2000048988A1 (en) * 1999-02-18 2000-08-24 F. Hoffmann-La Roche Ag Phenylalaninol derivatives
WO2001085196A2 (en) * 2000-05-09 2001-11-15 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2002000687A2 (en) * 2000-06-27 2002-01-03 The University Of British Columbia Antimicrobial peptides and methods of use thereof
WO2002018320A2 (en) * 2000-08-31 2002-03-07 Tanabe Seiyaku Co., Ltd. INHIBITORS OF α4 MEDIATED CELL ADHESION
EP1247533A2 (en) * 2001-04-05 2002-10-09 Pfizer Products Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
US20020155468A1 (en) * 1999-09-23 2002-10-24 Corixa Corporation Ovarian tumor antigen and methods of use therefor
KR20030021857A (en) * 2001-09-08 2003-03-15 주식회사 에코윈 Anticancerigenic Agent Including Copper(Ⅱ) Aminoacidate 1:1 Complex And Method Of Preparing The Same
WO2003102023A1 (en) * 2002-05-29 2003-12-11 Immatics Biotechnologies Gmbh Tumour-associated peptides that bond to mhc molecules
EP1371660A1 (en) * 2002-06-14 2003-12-17 Consejo Superior De Investigaciones Cientificas Vaccine
WO2004000870A2 (en) * 2002-06-19 2003-12-31 Lipps Binie V Two synthetic peptides for treatment and prevention of cancers
US20040121952A1 (en) * 1997-05-21 2004-06-24 Children's Medical Center Corporation Treatment of cancer
WO2004067023A2 (en) * 2003-01-30 2004-08-12 Survac Aps Survivin-derived peptides and use thereof
WO2004087167A2 (en) * 2003-04-04 2004-10-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
WO2004089310A2 (en) * 2003-03-31 2004-10-21 The Board Of Regents Of The University Of Texas System High-throughput assay for virus entry and drug screening
EP1589030A1 (en) * 2004-04-14 2005-10-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Bob-1 specific T cells and methods to use
WO2006086321A2 (en) * 2005-02-09 2006-08-17 Helix Biomedix Inc. Antimicrobial hexapeptides
WO2007004613A1 (en) * 2005-07-01 2007-01-11 Ajinomoto Co., Inc. THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE AND TNF-α PRODUCTION INHIBITOR

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01146817A (en) * 1987-12-02 1989-06-08 Norio Shimura Agent for alleviating acquired immune deficiency syndrome
EP0443891A1 (en) * 1990-01-25 1991-08-28 Adir Et Compagnie Use of N-myristoyl-(S)-phenylalanine for the preparation of a medicament for the treatment of disorders by inhibiting the myristoylation
WO1992021368A1 (en) * 1991-06-06 1992-12-10 Life Sciences' Technologies, Inc. Composition and method for disease treatment
US20040121952A1 (en) * 1997-05-21 2004-06-24 Children's Medical Center Corporation Treatment of cancer
DE19734161A1 (en) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh Antagonists of stroma cell-derived factor-1, for diagnosis and treatment of human immune deficiency virus (HIV) infection
WO1999056764A1 (en) * 1998-04-30 1999-11-11 Teijin Limited Method for preventing or treating a human immunodeficiency virus infection
WO1999065479A1 (en) * 1998-06-19 1999-12-23 Bryan Thomas B Method of treating an autoimmune disorder
EP1004302A2 (en) * 1998-10-29 2000-05-31 Ajinomoto Co., Ltd. Immunomodulator
WO2000048988A1 (en) * 1999-02-18 2000-08-24 F. Hoffmann-La Roche Ag Phenylalaninol derivatives
US20020155468A1 (en) * 1999-09-23 2002-10-24 Corixa Corporation Ovarian tumor antigen and methods of use therefor
WO2001085196A2 (en) * 2000-05-09 2001-11-15 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2002000687A2 (en) * 2000-06-27 2002-01-03 The University Of British Columbia Antimicrobial peptides and methods of use thereof
WO2002018320A2 (en) * 2000-08-31 2002-03-07 Tanabe Seiyaku Co., Ltd. INHIBITORS OF α4 MEDIATED CELL ADHESION
EP1247533A2 (en) * 2001-04-05 2002-10-09 Pfizer Products Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
KR20030021857A (en) * 2001-09-08 2003-03-15 주식회사 에코윈 Anticancerigenic Agent Including Copper(Ⅱ) Aminoacidate 1:1 Complex And Method Of Preparing The Same
WO2003102023A1 (en) * 2002-05-29 2003-12-11 Immatics Biotechnologies Gmbh Tumour-associated peptides that bond to mhc molecules
EP1371660A1 (en) * 2002-06-14 2003-12-17 Consejo Superior De Investigaciones Cientificas Vaccine
WO2004000870A2 (en) * 2002-06-19 2003-12-31 Lipps Binie V Two synthetic peptides for treatment and prevention of cancers
WO2004067023A2 (en) * 2003-01-30 2004-08-12 Survac Aps Survivin-derived peptides and use thereof
WO2004089310A2 (en) * 2003-03-31 2004-10-21 The Board Of Regents Of The University Of Texas System High-throughput assay for virus entry and drug screening
WO2004087167A2 (en) * 2003-04-04 2004-10-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
EP1589030A1 (en) * 2004-04-14 2005-10-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Bob-1 specific T cells and methods to use
WO2006086321A2 (en) * 2005-02-09 2006-08-17 Helix Biomedix Inc. Antimicrobial hexapeptides
WO2007004613A1 (en) * 2005-07-01 2007-01-11 Ajinomoto Co., Inc. THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE AND TNF-α PRODUCTION INHIBITOR

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 54, no. 2, 15 March 2003, Columbus, Ohio, US; abstract no. 142:212315, BANG, J.H.: "Anticancer agent containing aminoacid anion-cuprous complex" XP002436870 *
CHEMICAL ABSTRACTS, vol. 54, no. 2, 2002, Columbus, Ohio, US; abstract no. 141:257248, JANISZEWSKA J. ET AL.: "Small peptide dendrimers with antimicrobial properties." XP002473337 *
DATABASE BIOS 1982, SAVA G. ET AL.: "Anti-tumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P-388 leukemia and B-16 melanoma in mice.", XP002436871 *
DATABASE WPI Week 1989, Derwent World Patents Index; AN 1989-210008, XP002436873, "Agent for the treatment of AIDS comprising D-phenylalalnine and/or L-phenylalanine" *
JANISZEWSKA J. ET AL.: "peptides 2002, Proceedings of the European Peptide Symposium 27th, Sorrento, Italy", 31 August 2002, EDIZIONI ZIINO, CASTELLAMARE DI STABIA, ITALIA *
PALLADINO P. ET AL.: "Structural determinants of unexpected agonist activity in a retro-peptide analogue of the SDF-1alpha N-terminus.", FEBS LETTERS, vol. 579, September 2005 (2005-09-01), pages 5293 - 5298, XP002473335 *
SAVA G. ET AL.: "Anti-tumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P-388 leukemia and B-16 melanoma in mice.", CANCER TREATMENT REPORTS, vol. 66, no. 1, 1981, pages 179 - 182 *
SLOTIN L. A. ET AL.: "Water-soluble lysine-containing polypeptides. IV. The synthesis, characterization and circular dichroism spectra of sequential polypeptides formed from dipeptides of lysine and aminoacids of increasing side chain size.", CAN. J. CHEM., vol. 55, 1997, pages 4257 - 4266, XP002473336 *
ZHAO ET AL: "Investigation of interaction of oligopeptides with heparin", PAPERS PRESENTED AT THE MEETING - AMERICAN CHEMICAL SOCIETY. DIVISION OF POLYMER CHEMISTRY, XX, XX, vol. 37, no. 2, 1996, pages 153 - 154, XP009097385, ISSN: 0032-3934 *

Also Published As

Publication number Publication date
JP2009521917A (en) 2009-06-11
EP1971356A2 (en) 2008-09-24
IL172896A0 (en) 2006-06-11
CA2635770A1 (en) 2007-07-05
WO2007074456A2 (en) 2007-07-05
IL192372A0 (en) 2008-12-29
AU2006329534A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2007074456A3 (en) Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids
WO2008021379A3 (en) Increased activity and efficiency of expansin-like proteins
WO2006111524A3 (en) Il-21 variants
WO2004089396A3 (en) Anti-fungal peptidomimetics
WO2007006307A3 (en) Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
CR7875A (en) IMMUNOGLOBIN VARIANTS AND USES OF THIS
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2007039728A3 (en) AVß6 PEPTIDE LIGANDS AND THEIR USES
EP2270155A3 (en) Bitter taste receptors
WO2007097993A3 (en) Media conditioned by human embryonic stem cells or other progenitor cells and uses therefor
WO2007047969A3 (en) Methods of decreasing vascular calcification using il-1 inhibitors
WO2004069146A3 (en) L-dopa amide derivatives and uses thereof
WO2006104536A8 (en) Polynucleotides encoding stem cell factor-like proteins
WO2008093058A3 (en) Peptides and their use
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2007056389A3 (en) Synthesis and use of novel inhibitors and inactivators of protein arginine deiminases
WO2007100874A3 (en) Compositions containing peptides with non-natural amino acids and methods of use
WO2006054262A3 (en) Use of phage display technique for identifying peptides capable of binding progenitor/stem cells, peptides thereby obtained and uses thereof
JP2006508095A5 (en)
WO2006042661A3 (en) Oligopeptides and their use in cosmetics
WO2004078927A3 (en) Progenitor cells and methods of using same
EP2341147A3 (en) Preprimitive streak and mesendoderm cells
WO2007002739A3 (en) Chromium-amino acid complexes in the treatment of diabetes and other diseases
WO2005011728A3 (en) Use of soluble cd164 in inflammatory and/or autoimmune disorders
EP1922328A4 (en) Peptides targeted to protein kinase c isoforms and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006329534

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2635770

Country of ref document: CA

Ref document number: 2008548073

Country of ref document: JP

Ref document number: 2006821674

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006329534

Country of ref document: AU

Date of ref document: 20061227

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006329534

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006821674

Country of ref document: EP